TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe.
Szymańska K, Moore LE, Rothman N, Chow WH, Waldman F, Jaeger E, Waterboer T, Foretova L, Navratilova M, Janout V, Kollarova H, Zaridze D, Matveev V, Mates D, Szeszenia-Dabrowska N, Holcatova I, Bencko V, Le Calvez-Kelm F, Villar S, Pawlita M, Boffetta P, Hainaut P, Brennan P.
Szymańska K, et al. Among authors: navratilova m.
Cancer Lett. 2010 Jul 1;293(1):92-8. doi: 10.1016/j.canlet.2009.11.024. Epub 2010 Feb 6.
Cancer Lett. 2010.
PMID: 20137853